These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19442047)

  • 1. Interaction of ABC multidrug transporters with anticancer protein kinase inhibitors: substrates and/or inhibitors?
    Hegedus C; Ozvegy-Laczka C; Szakács G; Sarkadi B
    Curr Cancer Drug Targets; 2009 May; 9(3):252-72. PubMed ID: 19442047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?
    Brózik A; Hegedüs C; Erdei Z; Hegedus T; Özvegy-Laczka C; Szakács G; Sarkadi B
    Expert Opin Drug Metab Toxicol; 2011 May; 7(5):623-42. PubMed ID: 21410427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
    Pérez-Tomás R
    Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.
    Wu S; Fu L
    Mol Cancer; 2018 Feb; 17(1):25. PubMed ID: 29455646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins.
    Wang XK; Fu LW
    Curr Drug Metab; 2010 Sep; 11(7):618-28. PubMed ID: 20812904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug resistance: molecular mechanisms and clinical relevance.
    Ling V
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.
    Beretta GL; Cassinelli G; Pennati M; Zuco V; Gatti L
    Eur J Med Chem; 2017 Dec; 142():271-289. PubMed ID: 28851502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.
    Anreddy N; Gupta P; Kathawala RJ; Patel A; Wurpel JN; Chen ZS
    Molecules; 2014 Sep; 19(9):13848-77. PubMed ID: 25191874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade.
    Kathawala RJ; Gupta P; Ashby CR; Chen ZS
    Drug Resist Updat; 2015 Jan; 18():1-17. PubMed ID: 25554624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters.
    Ozvegy-Laczka C; Cserepes J; Elkind NB; Sarkadi B
    Drug Resist Updat; 2005; 8(1-2):15-26. PubMed ID: 15939339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration.
    Krchniakova M; Skoda J; Neradil J; Chlapek P; Veselska R
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance.
    Karthikeyan S; Hoti SL
    Anticancer Agents Med Chem; 2015; 15(5):605-15. PubMed ID: 25584696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic potential of targeting ABC transporters to combat multi-drug resistance.
    Bugde P; Biswas R; Merien F; Lu J; Liu DX; Chen M; Zhou S; Li Y
    Expert Opin Ther Targets; 2017 May; 21(5):511-530. PubMed ID: 28335655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Understanding of Interactions between Nanoparticles and ABC Transporters in Cancer Cells.
    Yin J; Deng X; Zhang J; Lin J
    Curr Med Chem; 2018; 25(42):5930-5944. PubMed ID: 29542407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting the ABCs of multidrug resistance in cancer chemotherapy.
    Tiwari AK; Sodani K; Dai CL; Ashby CR; Chen ZS
    Curr Pharm Biotechnol; 2011 Apr; 12(4):570-94. PubMed ID: 21118094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational ABC transporter inhibitors.
    Falasca M; Linton KJ
    Expert Opin Investig Drugs; 2012 May; 21(5):657-66. PubMed ID: 22493979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.
    Cihalova D; Staud F; Ceckova M
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):105-16. PubMed ID: 25986678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR.
    Mohammad IS; He W; Yin L
    Biomed Pharmacother; 2018 Apr; 100():335-348. PubMed ID: 29453043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
    Deng J; Shao J; Markowitz JS; An G
    Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.